Earnings Call · Q1 FY2022·2022-05-09

Q1 22EPS -20.69%·Rev n/aQ4 21EPS -21.21%·Rev n/aQ3 21EPS -17.24%·Rev n/aQ2 21EPS -64.52%·Rev n/a⚠ consensus missing

Akebia Therapeutics, Inc. AKBA

Mercedes Carrasco — Director of Corporate Communications

John Butler — Chief Executive Officer

David Spellman — Chief Financial Officer

+23.9%1d on move date+23.7% vs SPY3d+19.5%5d+10.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AKBA calls or request research access.

More AKBA calls Browse calls Request research access